Terms ending in 2040
Every in-force patent on Merck Sharp and Dohme LLC's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,515,007 | In Silico Process for Selecting Protein Formulation Excipients In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,291,570 | Treatment of Metastatic Pancreatic Adenocarcinoma In force · High confidence | Biolinerx Ltd. and Merck Sharp & Dohme Corp. | In force | High confidence | |
| US 11,377,438 | 2-Amino-N-HETEROARYL-NICOTINAMIDES as NAV1.8 Inhibitors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,427,616 | PCSK9 Antagonist Compounds In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,098,029 | 5-Alkyl Pyrrolidine Orexin Receptor Agonists In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,331,018 | Pyrrolidine Orexin Receptor Agonists In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,872,558 | Well Plate Assembly with Pressure Release Mechanism In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,471,512 | Pharmaceutical Compositions of a Peptide In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,545,270 | Dossier Change Control Management System In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,312,719 | 9-Substituted Amino Triazolo Quinazoline Derivatives as Adenosine Receptor Antagonists, Pharmaceutical Compositions and Their Use In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| 20 more term ends in 2040 · Pro | |||||
10 of 30 patents shown. Soonest term end first, then patent number.
Pro members see all 30.
29 of these are in force and held by Merck Sharp and Dohme LLC.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.